SCPX
PINK Scorpius Holdings, Inc.$0.0002 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.0002, and at the day’s high of $0.0002
- YTD change
- +0.00%
- vs 20-day SMA
- -87.40%
- vs 200-day SMA
- -95.42%
Price ranges
Price & Performance
-0.01 (-98.00%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 100.0% away from all-time highs of $7.2192
- SCPX is up 0% since the beginning of the year
- SCPX is down 98% over the past 12 months
- SCPX is down 90% over the past 1 month
- 0% of all SCPX investors are betting against SCPX
SCPX reads n/a: price sits below both the 20- and 200-day averages, the 12-month move is -33.3%.
- Previous minute
- +$0.0000
- Last hour
- +$0.0000
- Last 5 days
- -80.00%
- vs 8-day SMA
- -70.37%
No alerts for SCPX in the last day.
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in San Antonio, TX.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
